Related Experiment Videos
Adjuvant therapy for pancreatic cancer
Swiss Surgery = Schweizer Chirurgie = Chirurgie Suisse = Chirurgia Svizzera
|November 15, 2000
Summary
Adjuvant chemotherapy, not chemoradiotherapy, improves survival for pancreatic cancer patients. Ongoing trials like ESPAC-3 aim to confirm these findings for better treatment outcomes.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Pancreatic cancer treatment has historically offered limited hope.
- Recent advances in specialized treatment centers have improved surgical resection outcomes.
- Chemotherapy has shown promise in managing advanced pancreatic cancer.
Purpose of the Study:
- To evaluate the efficacy of adjuvant therapy in pancreatic cancer.
- To determine the survival benefit of post-operative chemoradiotherapy versus chemotherapy.
- To clarify the role of adjuvant chemotherapy in improving pancreatic cancer survival rates.
Main Methods:
- Review of historical randomized controlled trials, including a small GITSG study.
- Analysis of recent large-scale trials by EORTC and ESPAC comparing chemoradiotherapy with other treatments.
- Focus on ongoing ESPAC-3 trial designed to definitively assess adjuvant chemotherapy efficacy.
Main Results:
- A small study suggested survival benefits from combined chemoradiotherapy and chemotherapy.
- Large EORTC and ESPAC trials found no benefit from chemoradiotherapy alone.
- Evidence from Norwegian and ESPAC studies indicates that adjuvant chemotherapy alone prolongs survival.
Conclusions:
- Adjuvant chemotherapy, without chemoradiotherapy, appears to be a beneficial treatment for pancreatic cancer.
- Further research, such as the ESPAC-3 trial, is crucial to solidify these findings.
- The new millennium offers increased hope for managing pancreatic cancer effectively.